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ditioning regimen (RIT). Infections were evaluated in view of the
immune suppression the regimen provided. Methods: Condition-
ing consisted of alemtuzumab 3 (day 34 to 18), ﬂudarabine
(day 8 to 4), and melphalan (day -3). Of 23 recipients, 10
were sibling and 13 unrelated transplants. Diagnoses included bone
marrow failure (7), hemoglobinopathies (2), immune dysregulation
(3), immune deﬁciency (5), metabolic disorders (5), and Evan
syndrome (1). Twelve were bone marrow, 6 peripheral blood, and
5 umbilical cord blood grafts. Infections were classiﬁed by time of
onset as conditioning to day 30 (Period 1), day 31 to 100
(Period 2), day 101 to 180 (Period 3), and day 181 to 365
(Period 4). Immune reconstitution was monitored serially. Re-
sults: All but 1 patient stably engrafted donor cells (95%). The
table shows the incidence, etiology, and timing of infections en-
countered. The frequency of infections was highest until day100
and tapered signiﬁcantly after day 180. This correlated with B
cell numbers and immune globulin levels that normalized at day
180. The median absolute lymphocyte count was 	1000/cu.mm
and absolute CD4 T cell number was 	400/cu.mm at 6 months
post-transplant. No fungal infections were encountered after day
180. Infection was documented after day 180 only 1 patient
who was on multiagent therapy for extensive chronic GVHD.
Acute and chronic GVHD rates were 12% each. CMV, a common
pathogen associated with alemtuzumab, was detected within day
100 in 9 of 10 cases; there was no CMV infection after day180.
There were 3 infection-related deaths. Two died from Pseudomonas
sepsis which pre-dated transplant and progressed after, and 1 ex-
pired due to CMV disease. No deaths have occurred since insti-
tuting bacterial and fungal prophylaxis during the early post trans-
plant period. Conclusions: Stable engraftment was achieved in
patients at high risk for graft rejection. Infectious complications
correlated with immune reconstitution kinetics and should be care-
fully monitored during the vulnerable period. Satisfactory immune
reconstitution parameters were evident in the latter half of the ﬁrst
year post-transplant reducing vulnerability to infectious complica-
tions (Table1).




Infections Bacterial Viral Fungal
Period 1 23/32 19 10 3
Period 2 20/24 15 9 0
Period 3 14/13 7 5 1
Period 4 11/2 1 1 0
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Many BMT programs are challenged with ﬁnancial justiﬁcation
of their existence. One way to maximize reimbursement within
your own facility is to induct a member of your IS department as
a core member of your BMT team. Begin by identifying a person
in your IS department who can work with the software applications
utilized by your program. Many hospitals have an electronic med-
ical record system, which is a repository of clinical data. Integrating
this information with the existing admission/discharge/transfer
systems allows for extended data analysis that can be used for
monitoring reimbursement activities. This integration and report-
ing will require support from an IS staff member, so inclusion of
this person in the BMT program will allow for improved under-
standing of BMT program requirements. At our center, a trans-
plant speciﬁc information system was developed which allowed for
data to be entered by staff according to their responsibility. Refer-
ral, ﬁnancial, clinical, laboratory, and clerical information is en-
tered and is available in real-time to all users. In addition, users can
create their own ad hoc queries based on 18 categories of selection
criteria and 78 display parameters. These reports can quickly show
populations of transplanted patients with common characteristics
and their comparative outcomes. This data can then be exported to
allow for independent analysis by pulling in cost data from ﬁnancial
software. This advantage is carried over to the contracting/man-
aged care staff (CMC). By looking at historical data, the CMC staff
can better determine the changing costs related to diagnosis and
type of transplant. Data such as readmissions, donor lymphocyte
infusions, long-term follow-up, and engraftment information can
be queried and can be compared to costs associated. With this
information, the CMC can now better analyze the need for adjust-
ment in payment on contractual agreements with third party pay-
ors. As technology evolves and new drugs and treatments become
standard of care, the CMC can monitor and make changes as
contract renewals are considered. In addition, long-term agree-
ments (3 to 5 years) can be adjusted with real data for justiﬁcation.
Finally, this data can be used to look at year-end reports, patient-
speciﬁc reports, and payor-speciﬁc reports. This information is key
to determining the ﬁnancial viability of your program.
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Nearly 700 haematopoietic stem cell transplants have been per-
formed at the Singapore General Hospital since 1985. Over the
years, conditioning regimens, indications, choices of hematopoietic
stem cells and transplant outcomes have evolved in tandem with
advances and trends in the medical and scientiﬁc community. Such
practices vary between countries and even between institutions
within the same city. Up to September 2005, there were 76 non-
myeloablative transplants and 573 myeloablative transplants. In
our own center, bone marrow was the chosen source of hemato-
poietic stem cells (HSC) in between 100% of patients between the
years 1985 to 1987, but fell to 70.5 in 1995 and 11.1% in the last
one year. The percentage of patients transplanted for the various
illnesses was: acute leukemia 66.7% in 1985, 42.9% in 1995, and
41.9% in 2005; chronic myeloid leukemia 33.3% in 1985, 16.7%
and 3.2% in 2005; multiple myeloma 0% in 1985, 7.1% in 1995
and 22.6% in 2005; lymphoma 0% in 1985, 2.4% in 1995, and
25.8% in 2005. One hundred day transplant related mortality all
the patients, which was 100% in 1985 when the program started,
fell to 35.7% in 1995, 22.5% in 2001, then stabilising at about 28%
in the last few years, as increasingly more complex cases were taken
on. For autologous transplants, however, the transplant related
mortality has remained between 3 to 5%. In this presentation of
the evolving trends in HSCT observed within our own institution,
we also postulate on the future directions that our center and,
possibly, other Asian transplant centers will take in the coming
decade.
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